ASTRANA HEALTH INC (ASTH)
Health Care · Managed Healthcare / Value-Based Care · NASDAQ
Astrana Health is a physician-centric, technology-enabled platform that manages care and operations for value-based healthcare providers serving Medicare and Medicaid patients.
What ASTRANA HEALTH INC does
Astrana Health is a healthcare delivery platform that operates through a network of affiliated medical groups and independent practice associations (IPAs). The company manages healthcare services primarily for government-sponsored programs, focusing on value-based care models, including the Medicare Shared Savings Program (MSSP) and various CMS innovation models like ACO REACH and ACO LEAD. Its operations encompass clinical care management, administrative support for physicians, and laboratory services.
Themes: value-based care, Medicare Advantage / Medicare programs, healthcare IT infrastructure, physician practice management
Fundamentals
- Price$38.58 as of 2026-10-20 close
- Market cap$2.2B as of 2026-08-03 (share count; price 2026-10-20)
- 1-year return+16.9% 2025-10-20 close $32.99 → 2026-10-20 close $38.58
- P/E47.05 as of 2026-10-20
- Net margin+0.7% FY2025, SEC XBRL
- ROE+2.8% FY2025, SEC XBRL
- ROIC+4.3% NOPAT / (debt + equity - cash), average capital — 10-K FY2025 (year ended 2025-12-31)
- Debt / equity1.13 borrowings, leases excluded / equity — 10-Q/10-K balance sheet 2026-06-30
- Revenue growth (YoY)+56.4% FY2025, SEC XBRL
- Revenue CAGR (3y)+40.6% SEC XBRL
- Beta0.64 as of 2026-09-03
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
Dividend: pays a dividend.
How ASTH compares in its sector
- price-to-earnings ratiotop 25% 181 covered Health Care peers, as of 2026-10-20
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-03
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRtop 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
ASTH is not currently in any published Top 10 list. Its scores are below.
Top 10 score
47.0 #833 of 1,265 scored · #106 of 146 in Health Care
Growth 95th (3-year revenue CAGR 40.6%, revenue growth year over year 56.4%) and trend 59th (trading above its 200-day average); weakest is capital return (20th, net share count bought back over the year -2.9).
Scores as of 20 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
Dividend coverage (FY2025)
Covered by reported results. In FY2025, ASTH's dividend was covered by reported results (earnings payout 35%, free-cash-flow payout 8%). This describes past coverage, not a forecast.
- Earnings payout35% dividends / net income
- Free-cash-flow payout8% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
Quarterly results
| Quarter | Revenue | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $973M | $34M | $20M | $0.40 | $33M† | $4M† |
| Q1 FY2026 2026-03-31 | $965M | $29M | $14M | $0.29 | $68M | $4M |
| Q4 FY2025 2025-12-31 | $951M† | $18M† | $6M† | $0.13† | -$3M† | $3M† |
| Q3 FY2025 2025-09-30 | $956M | $19M | $373000 | $0.01 | $10M† | $3M† |
| Q2 FY2025 2025-06-30 | $655M | $20M | $9M | $0.19 | $91M† | $1M† |
| Q1 FY2025 2025-03-31 | $620M | $21M | $7M | $0.14 | $17M | $3M |
| Q4 FY2024 2024-12-31 | $665M† | $720000† | -$7M† | -$0.14† | -$11M† | $3M† |
| Q3 FY2024 2024-09-30 | $479M | $28M | $16M | $0.33 | $34M† | $2M† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$401M
- Total debt$936M borrowings only; leases excluded
- Net debt$536M total debt − cash − short-term investments
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How ASTRANA HEALTH INC looks technically
ASTRANA HEALTH INC (ASTH) is trading 15.6% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 117 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 13, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 57, neither overbought (above 70) nor oversold (below 30). It just made a new 20-day high, its first since 2026-09-14, pushing above its recent trading range. It is 25.2% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 15.6% above its 200-day average, the long-term trend line — a longer-term uptrend | +15.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $37.27 | $37.27 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $33.37 | $33.37 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 36 calendar days ago — the swings before that are what the structure reading is measured on | 36 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 39.95. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 117 trading days ago — a "golden cross", a bullish long-term signal | 117 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 13, below the 25 that marks a real trend) | 12.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 57, neither overbought (above 70) nor oversold (below 30) | 57.3 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($34.71 to $39.87) — its "stochastic" reading is 75 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 75.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 13 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $51.60 | $51.60 |
|---|---|---|
| From the 52-week high | it is 25.2% below its 52-week high (its highest price of the past year) | -25.2% |
| Above the 52-week low | it is 113.4% above its 52-week low (its lowest price of the past year) | +113.4% |
| Below the 52-week high | it is 25.2% below its highest point of the past year | 25.2% |
| Since a 20-day breakout | it just made a new 20-day high, its first since 2026-09-14, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it made a new 55-day low about 22 trading days ago | 22 sessions |
| All-time high | its highest closing price on record is $133.23 (set on 2021-11-15) | $133.23 |
| Given back of the 52-week move | over the past year its closes ranged ($18.16 to $49.81), and it has given back roughly a third of its rise from last year’s low — 35% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $29.24 to $30.25. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 35.5% |
| From the all-time high | it is 71.0% below its all-time high | -71.0% |
| Nearest price level | it is trading 1.7% below a resistance level at $39.23 — a price it turned at three times since 2024-11-15, most recently on 2026-09-01. Since 2024-10-21 it has 13 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +1.7% |
| All-time low | its lowest closing price on record is $0.1 (set on 2009-07-20) | $0.1 |
| Above the all-time low | it is 38480.0% above its all-time low | +38,480% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 79% of it) | 21st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.70 between its high and its low — about 4.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.70 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $34.02 and $39.06 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $34.02 – $36.54 – $39.06 |
| Typical daily range (% of price) | its price moves about 4.4% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.4% |
| Stretch from the 200-day average | it is trading 3.1 daily ranges above its 200-day average price (15.6% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.1 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.64× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
3
| Since a doji | 3 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 3 sessions ago |
|---|---|---|
| Since a bullish engulfing | 7 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 7 sessions ago |
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-20 0.6% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +0.6% |
|---|---|---|
| Gap filled | a 5.8% gap down opened on 2026-09-23 has been "filled" 17 sessions ago — price traded back through the level the gap left behind, and it took 2 sessions to close | 17 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +4.81% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 11.3 percentage points (the stock gained 12.3% while the market gained 1.0%) | +11.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 17.0 percentage points (the stock lost 13.4% while the market gained 3.6%) | -17.0% |
| vs market, 6 months | over the past 6 months this stock beat the market by 14.2 percentage points (the stock gained 22.7% while the market gained 8.5%) | +14.2% |
| vs market, 12 months | over the past 12 months this stock beat the market by 2.4 percentage points (the stock gained 16.9% while the market gained 14.6%) | +2.4% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bearish state — these describe past price behaviour, not a forecast | 0 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 12.5% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 14% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $33.78 — a volume-weighted average of daily closes over 198 sessions, not a true tick-by-tick VWAP. | +14.2% |
|---|---|---|
| Vs the average paid since it last reported | the price is 5% above the average price paid since it last reported on 2026-08-06 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $36.76 — a volume-weighted average of daily closes over 53 sessions, not a true tick-by-tick VWAP. | +5.0% |
Double bottom, bullish — forming · entry $40.81 · 52 sessions in
Price levels it has turned at before
ASTH last closed at $38.58 on 2026-10-20. Since 2024-10-21 it has turned at 13 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $39.23 | Resistance | 1.7% above the last close | turned there three times · 2024-11-15 to 2026-09-01 |
| $39.97 | Resistance | 3.6% above the last close | turned there five times · 2025-02-18 to 2026-10-13 |
| $36.74 | Support | 4.8% below the last close | turned there three times · 2026-05-21 to 2026-09-09 |
| $34.97 | Support | 9.4% below the last close | turned there twice · 2025-02-06 to 2025-10-28 |
| $33.98 | Support | 11.9% below the last close | turned there four times · 2025-04-15 to 2026-08-06 |
| $45.05 | Resistance | 16.8% above the last close | turned there twice · 2024-12-02 to 2026-07-09 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $39.95.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This reading has stood for 22 trading days, since 2026-09-21.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Trading above the 50-day moving average · Pulled back from the 12-month high · Broke out to a new 20-day high · trendless / choppy (low ADX) · beating the market | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.36 mean, 1=Strong Buy…5=Strong Sell) — 9 analysts
- Mean price target$51.67 range $41.00 – $65.00; median $53.00
Analyst estimates, as of 2026-10-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ASTH
- Consensus EPS estimate$0.8767 next reporting period, as of 2026-10-19
- Estimate change, 30 days+$0.01667 (+1.9%) from $0.86, on 2026-09-15, 34-day window
- Readings revised upward20% of 10 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on CMS and state-sponsored programs for capitation payments","Regulatory and funding risks related to federal/state healthcare policy changes","Potential for cybersecurity breaches or disruptions to management information systems"]
What changed in the latest 10-Q
AI-assisted comparison of ASTH's 10-Q filed 2026-08-10 against the prior one filed 2026-05-08.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-08-10) includes a Condensed Consolidated Statements of Income table for the three months ended June 30, 2026 and 2025.
- Newer filing includes a Condensed Consolidated Statements of Income table for the six months ended June 30, 2026 and 2025.
- Newer filing states that as of June 30, 2026 and 2025, the company managed a total of 29 and 21 independent risk-bearing organizations, respectively.
- Newer filing reports patient count of approximately 1.5 million as of June 30, 2026.
- Removed:
- Older filing (2026-05-08) includes a 'Regulatory and Industry Trends' section discussing the April 6, 2026 CMS final 2027 Medicare Advantage and Part D payment rates.
- Older filing includes a Condensed Consolidated Statements of Income table for the three months ended March 31, 2026 and 2025.
- Older filing includes a 'Risk-Bearing Organizations and Patients' section reporting 29 and 20 independent risk-bearing organizations as of March 31, 2026 and 2025, respectively.
- Older filing includes a 'Revenue' discussion section describing total revenue of $965.1 million for the three months ended March 31, 2026 compared to $620.4 million for the prior year period.
- Reworded:
- Newer filing reports patient count of approximately 1.5 million as of June 30, 2026, whereas older filing reports approximately 1.55 million patients as of March 31, 2026.
- Newer filing states 'Leveraging our proprietary population health management...' ('our'), while older filing states 'Leveraging its proprietary population health management...' ('its').
- Newer filing states 'operate an integrated, value-based healthcare model that aims to empower the providers in our network', whereas older filing states 'operates an integrated, value-based healthcare model, that aims to empower the providers in its network'.
- Newer filing phrase 'cost-effective manner' has a hyphen, while older filing uses 'cost effective manner' without a hyphen.
- Notes:
- The newer filing text is truncated at the end, cutting off mid-sentence in the 'Risk-Bearing Organizations and Patients' section.
- The older filing text is truncated at the end, cutting off mid-sentence in the 'Revenue' discussion section.
- The older filing's revenue table breaks out revenue into multiple line items (Capitation, net; Risk pool settlements and incentives; Management fee income; Fee-for-service, net; Other revenue), while the newer filing uses a single 'Capitation and other revenue, net' line item, differing table structures prevent direct line-item comparison.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for ASTH — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
U.S. House trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 2 matched disclosures for ASTH from U.S. House Clerk Periodic Transaction Report filings.
U.S. House trading disclosures →Institutional ownership (13F)
5 institutional 13F filers reported holding ASTH as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 9,515,626
- Reported value $441,620,189
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about ASTH's institutional holders → See what each manager we track holds →
Short interest (FINRA)
ASTH had 3,087,127 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
ASTH had 5.54% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 5.8 days to cover at the same settlement.
- Reported short interest (shares) 3,087,127
- Short interest (% of shares outstanding) 5.54%
- Prior settlement (shares) 3,273,033
- Reported change -5.68%
- Days to cover (reported) 5.8
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Elevance Health (ELV)
- Centene (CNC)
- Humana (HUM)
- UnitedHealth Group (UNH)
- Agilon Health (AGL)
- Privia Health (PRVA)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ASTH vs…
ASTRANA HEALTH INC is found in…
Frequently asked questions
What does ASTRANA HEALTH INC (ASTH) do?
Astrana Health is a healthcare delivery platform that operates through a network of affiliated medical groups and independent practice associations (IPAs). The company manages healthcare services primarily for government-sponsored programs, focusing on value-based care models, including the Medicare Shared Savings Program (MSSP) and various CMS innovation models like ACO REACH and ACO LEAD.
What sector is ASTRANA HEALTH INC (ASTH) in?
ASTRANA HEALTH INC (ASTH) is classified in the Health Care sector. Its industry is Managed Healthcare / Value-Based Care. It trades on NASDAQ.
Does ASTH pay a dividend?
Yes — ASTRANA HEALTH INC (ASTH) pays a dividend (market data, as of 2026-09-03). Informational only — not financial advice.
Who are ASTRANA HEALTH INC's (ASTH) competitors?
Notable peers of ASTRANA HEALTH INC (ASTH) include Elevance Health, Centene, Humana, UnitedHealth Group and Agilon Health. This peer set is informational only — not financial advice.
Has there been recent U.S. House stock trading in ASTH?
Yes — we hold 2 matched STOCK Act disclosures for ASTH from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is ASTRANA HEALTH INC (ASTH) overbought or oversold right now?
ASTRANA HEALTH INC (ASTH) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 57, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ASTH come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.